All posts by Yves Barbier
Immunogenicity using ElectroChemiLuminesence Technology (MesoScale Discovery)
THE CHALLENGE Today’s rapid developments in biologics–including proteins, peptides, therapeutic antibodies, and immunotherapeutics–have resulted in new drug development challenges that require an extensive and in-depth understanding of bioanalysis/immunology and the development of GLP, GCLP, and GMP compliant assays. OUR STATE-OF... Read More
XXI. ANNUAL MEETING German Society for Gene Therapy
Texcell Team at the XXI annual meeting German Society for Gene Therapy. Read More
ImmunoProfiling Lab: PBMCs Isolation
THE CHALLENGE The efficiency of your vaccine candidate needs to be assessed in term of immunogenicity. Your drug may involuntarily impact the immune system (induction of drug/carrier specific T-cell response or specific antibodies). In order to address these 2 kind of issues,... Read More
How to choose the best service provider partner ?
THE CHALLENGES Contract research organisations (CRO) are an integral part of drug development. > 40% of Drug and Discovery process pass by CRO projects. More and more early development steps are devolved to CRO But how to choose the best... Read More